Chris Ryan

Precision Strategies and Targeted Combinations in GU Oncology: Expert Insights From ESMO 2025

October 29th 2025

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Dr Lynam on the Clinical Implications of Targeted Therapies in Ovarian Cancer

October 29th 2025

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

FDA Grants Breakthrough Device Designation to PlasmaSure for NMIBC

October 28th 2025

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma

October 28th 2025

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

Dr Lee on the Role of SABR in Non–Small Cell Lung Cancer Management

October 28th 2025

Percy Lee, MD, discussed the use of SABR within the larger radiation therapy paradigm for the management of non–small cell lung cancer.

Emerging Agents and Paradigm Shifts in Gynecologic Cancer: Expert Takeaways From ESMO 2025

October 28th 2025

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma

October 27th 2025

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

Serial ctDNA Testing Holds Potential to Further Personalize MIBC Management

October 27th 2025

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

Neladalkib Showcases Early Activity in ALK+ Solid Tumors

October 27th 2025

Neladalkib showed durable responses and good tolerability in ALK-positive solid tumors, including TKI-pretreated patients, in early ALKOVE-1 results.

ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

October 27th 2025

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

October 27th 2025

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Gedatolisib-Based Regimens May Advance PIK3CA Wild-Type Metastatic Breast Cancer Care

October 27th 2025

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC

October 24th 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia

October 24th 2025

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Dr Peters on Obrixtamig Plus Atezolizumab/Chemo in First-Line ES-SCLC

October 24th 2025

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

FDA Approval of Y-90 Resin Microspheres Marks a New Chapter for Radioembolization in Unresectable HCC

October 23rd 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer

October 23rd 2025

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

October 23rd 2025

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

PRO Data Further Support SERENA-6 Regimen in HR+ Breast Cancer After Emergence of ESR1 Mutations

October 22nd 2025

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.